✦ LIBER ✦

Clinical benefits of early treatment with Fabrazyme in Fabry disease

✍ Scribed by S. Waldek; M. Banikazemi; J. Bultas; W. Wilcox; C. Whitley; M. McDonald; R. Finke; S. Packman; D. Bichet; D. Warnock; B. Brenner; R. Desnick

Book ID: 117321757
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 126 KB
Volume: 29
Category: Article
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(07)80149-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fabrazyme® therapy in pediatric patients

Fabrazyme® therapy in pediatric patients with Fabry disease: Improvements in quality-of-life measures

✍ A. Tylki-Szymanska; D.P. Germain; J.E. Wraith; N. Guffon; Y.H. Lien; M. Tsimarat 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Clinical benefit of enzyme replacement t

Clinical benefit of enzyme replacement therapy in Fabry disease

✍ Breunig, F; Weidemann, F; Strotmann, J; Knoll, A; Wanner, C 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 113 KB

Early initiation of agalsidase beta trea

Early initiation of agalsidase beta treatment is associated with fewer clinical events in women with Fabry disease: Data from the Fabry Registry

✍ Hopkin, Robert; Mauer, Michael; Lemay, Roberta; Ortiz, Jose; Sims, Kathy; Waldek 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Dementia with cerebrovascular disease: t

Dementia with cerebrovascular disease: the benefits of early treatment

✍ R. J. Schindler 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Withdrawal of enzyme replacement therapy

Withdrawal of enzyme replacement therapy in Fabry disease: Indirect evidence of treatment benefit?

✍ M. West; K. Lemoine 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 180 KB

102 Withdrawal of enzyme replacement the

102 Withdrawal of enzyme replacement therapy in Fabry disease: Indirect evidence of treatment benefit?

✍ Michael West; Kaye LeMoine 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 45 KB